Your Outsourced Competitive Intelligence Team
Industry expert competitive intelligence research team for pharma, biotech, and biotech investors. Advance your clinical programs and invest in novel therapeutics with the complete competitive picture.
Researching The Ever-Changing Global Competitive Landscape for Your Asset Takes Time.
Let Us Do It For You.
We dive deep on every aspect of biotech competitive intelligence:
Drug Discovery Monitoring
We track every new development that occurs globally at the discovery and preclinical stages of drug development for any published results that may affect your asset's competitive thesis.
- Publication Monitoring
- Conference Research Presentations
- Patent Filings
Clinical Trial Developments
We review all clinical trial milestones, design protocols, and results to inform your clinical trial design strategy and understand how your asset stacks up against competitors on every metric (clinical profile, launch timeline, and more).
- Data Readout Review
- Trial Protocol Analyses
- Global Registry Monitoring
Regulatory Engagement Insights
We uncover the regulatory strategy of competitors to understand what works and what doesn't for the FDA and other regulators to help speed up drug development and increase the odds of approval.
- FDA Advisory Meeting Examinations
- Evidence Package Analyses
- Regulatory Outcomes Analyses
See Our Competitive Intelligence Research
We track every indication pipeline. Check out some of our research below:
Current State of the Alpha-Emitter Radioligand Therapy Drug Development Landscape
No alpha-emitting radioligand therapy has been approved anywhere in the world, despite two beta-emitting RLTs (Lutathera, Pluvicto) already reaching the market. AZD2265 (AstraZeneca) leads the alpha-emitter field in phase 3, followed by RYZ101 (BMS) in phase 1b/3 and AAA817 (Novartis) in phase 2/3. Novartis, which already owns both approved beta-emitting RLTs, is also fielding an alpha-emitting successor, while Perspective Therapeutics and Telix Pharma stand out as the most RLT-focused emerging biotechs. Actinium-225 is the dominant isotope across the pipeline, and China-based developers remain notably absent from the alpha-emitter space.
Read report →Lp(a) Drug Development Pipeline: The Genetically Determined Cardiovascular Disease Risk Factor
No Lp(a)-targeting therapy has been approved anywhere in the world, despite Lp(a) being a genetically determined, non-modifiable cardiovascular risk factor affecting roughly 20% of the global adult population. Four assets have reached phase 3 across three therapeutic modalities: pelacarsen (Novartis), olpasiran (Amgen), lepodisiran and muvalaplin (both Eli Lilly). A deeper pipeline of siRNA, GalNAc-conjugated siRNA, and in vivo gene-editing therapies is advancing behind them, with Eli Lilly fielding the broadest and most diversified portfolio of any single sponsor.
Read report →Menin Inhibitor Drug Development Landscape: Two AML Approvals and a Pipeline Eyeing Diabetes
Two menin inhibitors, revumenib and ziftomenib, reached the US market in 2024 and 2025 as the first therapies targeting the menin-KMT2A interaction in KMT2A-rearranged and NPM1-mutant leukemias. Eight additional small molecule menin inhibitors are in active clinical development, split between oncology combination regimens and an emerging application in type 2 diabetes. Every asset in the pipeline remains a small molecule inhibitor; menin degraders exist only in early discovery, positioning next-generation inhibitor combinations as the near-term answer to acquired resistance.
Read report →Built on data from
FDA
ClinicalTrials.gov
PubMed
SEC EDGAR
CMS
NICE
WHO ICTRP
ICER
EMAFDAClinicalTrials.govPubMedSEC EDGARCMSNICEWHO ICTRPICEREMAFDAClinicalTrials.govPubMedSEC EDGARCMSNICEWHO ICTRPICEREMAWhy choose Inflection Labs to run your competitive intelligence?
| Inflection Labs | DIY with AI | Consulting Firm | Full Time In-House CI Hire | |
|---|---|---|---|---|
Turnaround | Within days, by combining tech & domain expertise | Minutes, but needs heavy QA | 6–12 weeks, data is already stale | Weeks to ramp up |
Biopharma depth | Deep scientific, clinical, regulatory, and commercial expertise | Surface-level, highly prone to hallucination | Deep but specialized and narrow | Dependent on hire but often deep |
Cost | From $2K per month | Low tool cost, high time cost | $50K–$200K+ | $150K+/yr salary + benefits per hire |
Data sources | FDA, CT.gov, PubMed, SEC, HTAs, Patent Repos, Conference Repos | Public web + LLM training data (including low credibility sources) | Interviews + public data | Varies |
Exec Team & Board-ready output | Yes. Polished & cited, with easily traceable source data | Needs extensive editing & fact-checking | Yes, but outputs lack adapability | Varies |
Scalability | On-demand, any volume | Fast but inconsistent quality | Per project | Limited by headcount |
Inflection Labs
Within days, by combining tech & domain expertise
DIY + AI
Minutes, but needs heavy QA
Consulting Firm
6–12 weeks, data is already stale
In-House Hire
Weeks to ramp up
Inflection Labs
Deep scientific, clinical, regulatory, and commercial expertise
DIY + AI
Surface-level, highly prone to hallucination
Consulting Firm
Deep but specialized and narrow
In-House Hire
Dependent on hire but often deep
Inflection Labs
From $2K per month
DIY + AI
Low tool cost, high time cost
Consulting Firm
$50K–$200K+
In-House Hire
$150K+/yr salary + benefits per hire
Inflection Labs
FDA, CT.gov, PubMed, SEC, HTAs, Patent Repos, Conference Repos
DIY + AI
Public web + LLM training data (including low credibility sources)
Consulting Firm
Interviews + public data
In-House Hire
Varies
Inflection Labs
Yes. Polished & cited, with easily traceable source data
DIY + AI
Needs extensive editing & fact-checking
Consulting Firm
Yes, but outputs lack adapability
In-House Hire
Varies
Inflection Labs
On-demand, any volume
DIY + AI
Fast but inconsistent quality
Consulting Firm
Per project
In-House Hire
Limited by headcount
Frequently Asked Questions
Ready to get started?
Book a 30-minute scoping call, or tell us what you need and we'll get back to you within 24 hours.
Book a Call